Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

GSK Raises FY2025 Adj EPS Guidance from $4.59 to $4.73-$4.81 vs $4.38 Est; Raises FY2025 Sales Guidance from $42.713B to $44.855B-$45.277B vs $42.560B Est

Author: Benzinga Newsdesk | October 29, 2025 04:06am
GSK (NYSE:GSK) raises FY2025 Adj EPS guidance from $4.59 to $4.73-$4.81 vs $4.38 analyst estimate. Raises FY2025 sales outlook from $42.713 billion to $44.855 billion-$45.277 billion vs $42.560 billion estimate.

Posted In: GSK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist